Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=-program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=-program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=-program_officials" }, "data": [ { "type": "Grant", "id": "9119", "attributes": { "award_id": "5I01RX003618-02", "title": "Impact of COVID 19 on Mental Health, Relationship Functioning and VA Tele Mental Health Service Use in a Longitudinal Cohort Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-01", "end_date": "2021-12-30", "award_amount": null, "principal_investigator": { "id": 23618, "first_name": "SUZANNAH K", "last_name": "CREECH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1625, "ror": "", "name": "OLIN TEAGUE VETERANS CENTER", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1625, "ror": "", "name": "OLIN TEAGUE VETERANS CENTER", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "9130", "attributes": { "award_id": "75N92020C00006-P00004-9999-1", "title": "RAPID ACCELERATION OF DIAGNOTICS (RADX) ADVANCED TECHNOLOGIES PLATFORM RAPID ACCELERATION OF DIAGNOTICS (RADX) ADVANCED TECHNOLOGIES PLATFORM PROJECT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-07-29", "award_amount": 5665290, "principal_investigator": { "id": 24909, "first_name": "JAMES", "last_name": "LU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1799, "ror": "", "name": "HELIX", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1799, "ror": "", "name": "HELIX", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "To enable reopening and monitoring of industrial, educational, and public sectors, widespread diagnostic testing for SARS-CoV-2 is needed. Rapid scale up is required to meet the testing needs in the US. Helix OPCO, LLC will establish an FDA-approved polymerase chain reaction (PCR) SARS-CoV-2 test, under Emergency Use Authorization (EUA), and perform testing in a CLIA-certified laboratory. Testing capacity will be incrementally scaled up to establish a high-throughput laboratory capable of daily processing of 25k, then 50k, then 100k, and finally 150k PCR tests with processing and analysis completed within a day of sample receipt. A subset of samples will undergo full viral genome sequencing, with sequences uploaded to GISAID and other public databases. Characterized samples will be provided to the RADx Variants Task Force to ensure that testing technologies are capable of detecting the full spread of SARS-CoV-2 variants. Expanded testing capacity through an FDA EUA method will support the needs of the US to monitor viral spread, detect variants, and inform reopening and mitigation efforts", "keywords": [ "Acceleration", "Address", "Advisory Committees", "CLIA certified", "COVID-19 test", "COVID-19 testing", "Databases", "Diagnostic tests", "Ensure", "FDA Emergency Use Authorization", "FDA approved", "Industrialization", "Laboratories", "Logistics", "Methods", "Monitor", "Polymerase Chain Reaction", "Process", "Public Sector", "RADx", "RADx Advanced Technology Platforms", "Reagent", "Reproducibility", "SARS-CoV-2 variant", "Sampling", "Ships", "Specificity", "Specimen", "Technology", "Testing", "Training", "United States National Institutes of Health", "Variant", "Viral", "Viral Genome", "design", "genome sequencing", "laboratory equipment", "next generation sequencing", "risk mitigation", "sample collection", "scale up" ], "approved": true } }, { "type": "Grant", "id": "9131", "attributes": { "award_id": "75N92020P00171-P00003-0-1", "title": "SUPPLEMENTAL FUNDS TO PROVIDE RADX INFRASTRUCTURE SUPPORT THROUGH JULY 1, 2021", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-02", "end_date": "2021-04-30", "award_amount": 7499311, "principal_investigator": { "id": 23973, "first_name": "MARK", "last_name": "MARINO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has an open solicitation for proposals to provide up to $500 million across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.", "keywords": [ "American", "COVID-19", "COVID-19 detection", "COVID-19 diagnostic", "COVID-19 testing", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Contracts", "Department of Defense", "Development", "Device Designs", "Diagnostic tests", "Ensure", "Exhalation", "Funding", "Goals", "Home", "Improve Access", "Infrastructure", "Laboratories", "Life Cycle Stages", "Modification", "National Institute of Biomedical Imaging and Bioengineering", "Patients", "Performance", "Point of Care Technology", "Privatization", "Program Development", "RADx", "Readiness", "Research", "Saliva", "Sampling", "Seasons", "Sensitivity and Specificity", "Speed", "Structure", "Technology", "Test Result", "Testing", "Time", "TimeLine", "United States National Institutes of Health", "Validation", "Virus", "base", "commercialization", "cost", "design", "detection limit", "flu", "handheld mobile device", "home test", "improved", "innovation", "meetings", "novel", "point of care", "product development", "programs", "scale up", "technology development", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "9132", "attributes": { "award_id": "272201800008I-0-759302000002-1", "title": "Task C10: Chemical Synthesis and Process Optimization of an anti-viral for enteroviruses and coronaviruses", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-31", "end_date": "2021-05-30", "award_amount": 844080, "principal_investigator": { "id": 24910, "first_name": "GREG", "last_name": "MARTIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1800, "ror": "", "name": "ALBANY MOLECULAR RESEARCH, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1800, "ror": "", "name": "ALBANY MOLECULAR RESEARCH, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.", "keywords": [ "Antiviral Agents", "C10", "Chemistry", "Communicable Diseases", "Coronavirus", "Development", "Development Plans", "Drug Kinetics", "Enterovirus", "Evaluation", "In Vitro", "Interventional Agent Development", "Lead", "Microbiology", "Safety", "Services", "Support Contracts", "Therapeutic", "Toxicology", "Toxin", "chemical synthesis", "in vivo", "pathogen", "pre-clinical", "process optimization", "product development", "programs", "therapeutic development" ], "approved": true } }, { "type": "Grant", "id": "9133", "attributes": { "award_id": "272201800008I-0-759302000002-2", "title": "Task C10: Chemical Synthesis and Process Optimization of an anti-viral for enteroviruses and coronaviruses", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-31", "end_date": "2021-05-30", "award_amount": 281360, "principal_investigator": { "id": 24910, "first_name": "GREG", "last_name": "MARTIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1800, "ror": "", "name": "ALBANY MOLECULAR RESEARCH, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1800, "ror": "", "name": "ALBANY MOLECULAR RESEARCH, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.", "keywords": [ "2019-nCoV", "Antiviral Agents", "C10", "COVID-19", "Chemistry", "Communicable Diseases", "Coronavirus", "Development", "Development Plans", "Drug Kinetics", "Enterovirus", "Evaluation", "In Vitro", "Interventional Agent Development", "Lead", "Microbiology", "Safety", "Services", "Support Contracts", "Therapeutic", "Toxicology", "Toxin", "chemical synthesis", "in vivo", "novel coronavirus", "pathogen", "pre-clinical", "process optimization", "product development", "programs", "therapeutic development" ], "approved": true } }, { "type": "Grant", "id": "9141", "attributes": { "award_id": "75N92020C00009-P00002-9999-1", "title": "RADX PROGRAM: TECH PROJECT NO 6114 FLUIDIGM ADVANTA DX SARS-COV-2 RT-PCR ASSAY FOR SALIVA", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-09-30", "award_amount": 8580056, "principal_investigator": { "id": 24916, "first_name": "ANDREW", "last_name": "QUONG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1801, "ror": "", "name": "FLUIDIGM CORPORATION", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1801, "ror": "", "name": "FLUIDIGM CORPORATION", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Fluidigm's BioMark HD microfluidics platform addresses the massive demand for SARS-CoV-2 PCR testing- combining speed, minimal cost, and massive throughput unparalleled in the industry. Further advantages include flexibility to rapidly integrate new mutational markers or increase panel size to include additional infectious agents. This platform works with all clinical sample types. 1) Technology Development Our solution leverages Advantaâ„¢ Dx SARS-CoV-2 RT-PCR Assay submitted for an EUA, and two assays under development that can change the landscape for detection. This assay allows for up to 6000 samples per day on a single system. Additional assays address different needs in testing, throughput, specificity and sensitivity. Modifications to the current workflow increases throughput to 48,000 tests per day while maintaining the identity of each sample. To distinguish between SARS-CoV-2 infection and other respiratory viruses, we will deploy our multiplexed capability to create a pan-respiratory panel. Cost estimates are preliminary based on assumptions of volume and distribution model. To enable pre-symptomatic screening, we are working with the DARPA ECHO program on a host response signature that can be run on the same platform. 2) Scaleup In three months our goal is to scale up manufacturing to over one million tests per day delivering 80 million tests by end of year. Investments in incremental capacity will deliver a cumulative run rate of 4.5 million tests per day in mid 2021. These two components provide a robust platform for scale up of testing for SARS-CoV-2 that allows for the simultaneous detection of other respiratory pathogens.", "keywords": [ "2019-nCoV", "Address", "Biological Assay", "COVID-19 testing", "Clinical", "Detection", "Development", "Goals", "Immune response", "Industry", "Infectious Agent", "Investments", "Microfluidics", "Modeling", "Modification", "Mutation", "RADx", "Reverse Transcriptase Polymerase Chain Reaction", "Running", "SARS-CoV-2 infection", "Sampling", "Sensitivity and Specificity", "Speed", "System", "Testing", "Work", "base", "cost", "cost estimate", "flexibility", "manufacturing scale-up", "programs", "respiratory", "respiratory pathogen", "respiratory virus", "salivary assay", "scale up", "screening", "technology development" ], "approved": true } }, { "type": "Grant", "id": "9142", "attributes": { "award_id": "75N93020C00022-0-9999-1", "title": "DEVELOPMENT OF FERRET REAGENTS FOR USE IN THE CHARACTERIZATION OF IMMUNE RESPONSES TO RESPIRATORY INFECTIONS IN THE FERRET MODEL.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-01", "end_date": "2022-06-30", "award_amount": 572817, "principal_investigator": { "id": 24917, "first_name": "TORI", "last_name": "RACE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Ferrets represent excellent models of human respiratory viruses such as influenza A virus, SARS-CoV and MERS-CoV. The goal of this proposal is to generate antibodies for analyzing immune cells and cytokine responses during respiratory infections in ferrets. The main focuses are immune cell markers and cytokines produced by these cells during immune responses. The contractor plans to use standard hybridoma techniques to generated monoclonal antibodies will then undergo extensive immunological characterization using various methods to show the specificity to recombinant immunogens as well as selected ferret samples.", "keywords": [ "Antibodies", "Antigens", "Cells", "Contractor", "Ferrets", "Generations", "Goals", "Hybridomas", "Immune", "Immune response", "Immunization", "Immunologics", "Influenza A virus", "Methods", "Middle East Respiratory Syndrome Coronavirus", "Modeling", "Monoclonal Antibodies", "Mus", "Proteins", "Reagent", "Recombinants", "Respiratory Tract Infections", "SARS coronavirus", "Sampling", "Specificity", "Techniques", "Validation", "cytokine", "human model", "respiratory virus", "response" ], "approved": true } }, { "type": "Grant", "id": "9143", "attributes": { "award_id": "26115003B91020F00001-P00004-0-2", "title": "COVID supplement: COMPUTING SERVICES FOR NCI DCCPS INCLUDING ANALYTICAL SUPPORT, SYSTEMS DEVELOPMENT, DATA MANAGEMENT AND INFRASTRUCTURE", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-03", "end_date": "2022-07-02", "award_amount": 500000, "principal_investigator": { "id": 24918, "first_name": "DAVID", "last_name": "RONEY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1802, "ror": "", "name": "INFORMATION MANAGEMENT SERVICES, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1802, "ror": "", "name": "INFORMATION MANAGEMENT SERVICES, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The Division of Cancer Control and Population Sciences (DCCPS) is one of the six Divisions of the National Cancer Institute (NCI), the largest of the National Institutes of Health (NIH). The DCCPS is the arm of the National Cancer Institute that both generates new knowledge and seeks to ensure that the products of cancer control research are effectively applied in all segments of the population. DCCPS is designed to: • understand the causes and distribution of cancer in populations, • support the development and implementation of effective interventions, and • monitor and explain cancer trends in all segments of the population. The objective of this contract is to provide support in the following 8 areas: (1) analytical support, (2) systems analysis, (3) data management and maintenance, (4) publication support, (5) computing infrastructure maintenance and support, (6) statistical methodology and programming and (7) WWW development and (8) Project management to support research efforts primarily or secondarily.", "keywords": [ "Area", "Cancer Control Research", "Contracts", "Development", "Division of Cancer Control and Population Sciences", "Ensure", "Infrastructure", "Internet", "Knowledge", "Maintenance", "Malignant Neoplasms", "Methodology", "Monitor", "National Cancer Institute", "Population", "Publications", "Research Support", "Support System", "Systems Analysis", "Systems Development", "United States National Institutes of Health", "arm", "coronavirus disease", "data infrastructure", "data management", "design", "effective intervention", "trend" ], "approved": true } }, { "type": "Grant", "id": "9144", "attributes": { "award_id": "26115003B91020F00001-P00001-0-2", "title": "COVID supplement: COMPUTING SERVICES FOR NCI DCCPS INCLUDING ANALYTICAL SUPPORT, SYSTEMS DEVELOPMENT, DATA MANAGEMENT AND INFRASTRUCTURE", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-03", "end_date": "2021-07-02", "award_amount": 400000, "principal_investigator": { "id": 24918, "first_name": "DAVID", "last_name": "RONEY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1802, "ror": "", "name": "INFORMATION MANAGEMENT SERVICES, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1802, "ror": "", "name": "INFORMATION MANAGEMENT SERVICES, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The Division of Cancer Control and Population Sciences (DCCPS) is one of the six Divisions of the National Cancer Institute (NCI), the largest of the National Institutes of Health (NIH). The DCCPS is the arm of the National Cancer Institute that both generates new knowledge and seeks to ensure that the products of cancer control research are effectively applied in all segments of the population. DCCPS is designed to: • understand the causes and distribution of cancer in populations, • support the development and implementation of effective interventions, and • monitor and explain cancer trends in all segments of the population. The objective of this contract is to provide support in the following 8 areas: (1) analytical support, (2) systems analysis, (3) data management and maintenance, (4) publication support, (5) computing infrastructure maintenance and support, (6) statistical methodology and programming and (7) WWW development and (8) Project management to support research efforts primarily or secondarily.", "keywords": [ "Area", "Cancer Control Research", "Contracts", "Development", "Division of Cancer Control and Population Sciences", "Ensure", "Infrastructure", "Internet", "Knowledge", "Maintenance", "Malignant Neoplasms", "Methodology", "Monitor", "National Cancer Institute", "Population", "Publications", "Research Support", "Support System", "Systems Analysis", "Systems Development", "United States National Institutes of Health", "arm", "coronavirus disease", "data infrastructure", "data management", "design", "effective intervention", "trend" ], "approved": true } }, { "type": "Grant", "id": "9149", "attributes": { "award_id": "75N92020F00202-P00002-0-1", "title": "PROJECT MANAGEMENT SUPPORT FOR COMMUNITY ENGAGEMENT ON TRANS-NIH THERAPEUTICS AND VACCINE TRIALS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-29", "end_date": "2021-01-28", "award_amount": 4297649, "principal_investigator": { "id": 24920, "first_name": "DANIEL", "last_name": "SHINGLEDECKER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1803, "ror": "", "name": "DELOITTE CONSULTING, LLP", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1803, "ror": "", "name": "DELOITTE CONSULTING, LLP", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Management support in setting up community engagement programs focused on populations most impacted by COVID-19 for Trans-NIH therapeutics and vaccine trials.", "keywords": [ "COVID-19", "Communication", "Communities", "Complex", "Development", "Population", "Structure", "Therapeutic Trials", "United States National Institutes of Health", "community engagement", "meetings", "outreach", "programs", "tool", "vaccine trial" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1424, "count": 14236 } } }